Intimation to stock Exchanges

Quick Explore

icon-pdf
Press Release - Cipla launches Cipremi (remdesivir lyophilised powder for injection 100 mg), the only U.S. FDA approved Emergency Use Authorisation (EUA) treatment for patients with severe COVID-19 disease
21st Jun 2020
icon-pdf
Newspaper Publication of Notice to Shareholders whose shares are liable to be transferred to IEPF
19th Jun 2020
icon-pdf
Press Release - Cipla expands partnership with Roche Pharma India to further improve access to key oncology medicines
18th Jun 2020
icon-pdf
Schedule of Analyst and Institutional Investors meetings
17th Jun 2020
icon-pdf
Acquisition of stake in Goapptiv Private Limited
10th Jun 2020
icon-pdf
Large Corporate Disclosure – FY 2019-20
10th Jun 2020
icon-pdf
Allotment of 31,762 equity shares under ESOS
01st Jun 2020
icon-pdf
Schedule of Analyst and Institutional Investors meetings
27th May 2020
icon-pdf
Schedule of Analyst / Institutional Investor meetings
22nd May 2020
icon-pdf
Cipla Limited receives final approval for generic version of Migranal® (Dihydroergotamine Mesylate Nasal Spray 4mg/mL) with a Competitive Generic Therapy Designation
21st May 2020
 
BSE and NSE Quotes by TradingView

The displayed data is not in real time and may have streaming delays.